Briefing Summary: US FDA Posts Advisory Committee Materials for Acadia’s Nuplazid (Pimavanserin) – MAR 29, 2016 (PDAC)

The US FDA has posted details, including company and FDA Briefing Materials, for the Tuesday, March 29, 2016 Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. The Committee will discuss the risk-benefit profile for a new drug application (NDA) for Nuplazid (pimavanserin), submitted by Acadia Pharmaceuticals Inc. (Acadia) for the proposed treatment of psychosis associated with Parkinson's disease (PDP).

See the SAC Tracker report